Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Lung Cancer
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 431
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 283 more

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions: Fezolinetant, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: COVID19
Interventions: RD-X19, Sham; Device
Lead sponsor: EmitBio Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Kalamazoo, Michigan + 6 more

Conditions: May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency
Interventions: Duo Venous Stent System; Device
Lead sponsor: Vesper Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 28
States / cities: Orange, California • Palo Alto, California • Darien, Connecticut + 24 more

Conditions: Prostate Adenocarcinoma
Interventions: Dietary Intervention, Questionnaire Administration; Combination Product · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cystic Fibrosis
Interventions: Nitric Oxide 160 ppm; Drug
Lead sponsor: Novoteris, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more

Conditions: Neutropenia, Breast Cancer
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 49
States / cities: Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more

Conditions: Crohn's Disease
Interventions: GSK1605786A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 35 more

Conditions: IBD
Interventions: Biofeedback, Music Relaxation Therapy; Behavioral · Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Primary Hyperaldosteronism
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more

Conditions: Restless Legs Syndrome
Interventions: Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 52
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions: MT-4561; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more

Conditions: Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions: ABT-751, quality-of-life assessment; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 8 more

Conditions: Pancreatic Cancer
Interventions: CA 19-9 Assay; Other
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 6
States / cities: Boca Raton, Florida • Fort Lauderdale, Florida • Baltimore, Maryland + 3 more

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 16,372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 139
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more

Conditions: Obesity, Endotoxemia, Inflammation
Interventions: Green Tea Extract, Placebo; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Polypharmacy
Interventions: interdisciplinary polypharmacy clinic visit; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 56
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more

Conditions: Lymphoma
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 203
States / cities: Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 137 more

Conditions: PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 184
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more

Conditions: Knee Osteoarthritis
Interventions: Hylan G-F 20, Control; Device · Other
Lead sponsor: OhioHealth; Other
Eligibility: 40 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alzheimer's Disease
Interventions: Aducanumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 104
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions: Dasatinib, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 184
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 144 more

Search by objective public record fields.

S9925: Collecting and Storing Samples From Patients With Lung Cancer

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Impact of a Biofeedback Intervention on Microbiome, Metabolome, and Clinical Outcomes in Pediatric IBD (Study 2)

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Longitudinal Pancreatic Cancer Study

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults

Measuring the Impact of an Interdisciplinary Polypharmacy Clinic Within a Patient-centered Medical Home

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma